Imagine a single shield that protects you from several different types of dangerous viruses instead of needing a separate one for each. This work creates a 'master key' vaccine that covers multiple deadly viruses like Ebola and Marburg. It also builds a library of options to quickly fight off new, unknown versions of these diseases.
Filovirus outbreaks cause extreme fatality rates and massive economic instability, including a US $53.19 billion burden from a single major event. Current responses are reactive rather than preventive.
Multivalent vaccines with phase II clinical data and a vaccine library of all known Filoviruses with phase I clinical data.
If you are a vaccine manufacturer dealing with the high risk of unpredictable outbreaks — this project developed multivalent vaccines that provide a pathway to licensure. This allows for the production of a single product protecting against multiple Filoviruses.
If you are a health agency dealing with the risk of 90% fatality rates in endemic regions — this project developed a vaccine library and multivalent candidates. This prevents the massive economic losses, such as the US $53.19 billion burden seen in previous outbreaks.
If you are a CRO dealing with the need for rapid response to 'Disease X' — this project developed candidates with phase I and phase II clinical data. This provides a validated starting point for accelerating the 100 Days Mission.
The project has a total pool of 50m, consisting of 35m from Horizon Europe and 15m from CEPI.
The project aims for industrial-ready outputs, specifically multivalent vaccines with phase II clinical data and individual candidates with phase I clinical data to support licensure.
Based on available project data, the awards are administered and managed by the CEPI secretariat, but specific licensing terms are not detailed.
The project runs for 66 months, from May 1, 2024, to October 31, 2029.
The vaccines are designed for preventive vaccination campaigns in endemic regions, specifically targeting at-risk populations like health-care workers.
The project is managed by a single entity, the Coalition for Epidemic Preparedness Innovations (CEPI), based in Norway. While the consortium lists 0 industry or university partners, CEPI acts as a central funding and management hub that distributes awards to develop the vaccines, leveraging a total budget of 50m EUR.
Contact the CEPI secretariat for award management and licensure pathways.
Contact us to identify the specific vaccine candidates emerging from the FILOVAX library.
